// App-Quantinova.ai

8047 : Health-related quality of life over time in transplant-ineligible patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone until progression.

Researchers

Presenter

  • Dan T. Vogl

Principal Investigators

  • Michel Delforge

  • Kevin W. Song

  • Shien Guo

  • Craig J Gibson

  • Annette L. Ervin-Haynes

  • Thierry Facon

Medical Centers

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • KU Leuven, Leuven, Belgium

  • Vancouver General Hospital, Vancouver, BC, Canada

  • Evidera, Lexington, MA

  • Celgene Corporation, Summit, NJ

  • Service des Maladies du Sang, Hopital Claude Huriez, Lille, France

Locations

  • United States

  • Canada

  • France

  • Belgium

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00689936

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved